These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 7507404

  • 41. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
    Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK, Miller LL.
    Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
    [Abstract] [Full Text] [Related]

  • 42. Introduction to 5-fluorouracil modulation.
    Martin DS.
    Cancer Invest; 1990; 8(2):257-8. PubMed ID: 2400944
    [No Abstract] [Full Text] [Related]

  • 43. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
    Köhne CH, Schöffski P, Wilke H, Käufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dörken B, Schmoll HJ.
    J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
    [Abstract] [Full Text] [Related]

  • 44. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
    Benson AB.
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
    [Abstract] [Full Text] [Related]

  • 45. Failure of high-dose leucovorin to improve therapy with the maximally tolerated dose of 5-fluorouracil: a murine study with clinical relevance?
    Martin DS, Stolfi RL, Colofiore JR.
    J Natl Cancer Inst; 1988 Jun 01; 80(7):496-501. PubMed ID: 3259266
    [Abstract] [Full Text] [Related]

  • 46. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
    Kemeny N, Schneider A, Martin DS, Colofiore J, Sawyer RC, Derby S, Salvia B.
    Cancer Res; 1989 Aug 15; 49(16):4636-9. PubMed ID: 2472883
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Johnston PG, Benson AB, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ.
    J Clin Oncol; 2003 Mar 01; 21(5):815-9. PubMed ID: 12610179
    [Abstract] [Full Text] [Related]

  • 50. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
    Blanke CD, Shultz J, Cox J, Modiano M, Isaacs R, Kasimis B, Schilsky R, Fleagle J, Moore M, Kemeny N, Carlin D, Hammershaimb L, Haller D.
    Ann Oncol; 2002 Jan 01; 13(1):87-91. PubMed ID: 11863117
    [Abstract] [Full Text] [Related]

  • 51. Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases.
    Leonard GD, Kemeny NE.
    Dis Colon Rectum; 2006 Mar 01; 49(3):407-10. PubMed ID: 16475032
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
    Valone FH, Friedman MA, Wittlinger PS, Drakes T, Eisenberg PD, Malec M, Hannigan JF, Brown BW.
    J Clin Oncol; 1989 Oct 01; 7(10):1427-36. PubMed ID: 2789272
    [Abstract] [Full Text] [Related]

  • 54. [Biomodulation of 5-fluorouracil by interferon].
    Aiba K.
    Gan To Kagaku Ryoho; 1995 Jul 01; 22(8):1018-27. PubMed ID: 7611752
    [Abstract] [Full Text] [Related]

  • 55. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
    Jodrell DI, Oster W, Kerr DJ, Canney PA, Yosef H, Steward WP, Kaye SB, Cassidy J.
    Eur J Cancer; 1994 Jul 01; 30A(7):950-5. PubMed ID: 7946590
    [Abstract] [Full Text] [Related]

  • 56. [The biochemical modulation of 5-fluorouracil by leucovorin].
    Borner M, Brunner K.
    Schweiz Med Wochenschr; 1991 Aug 17; 121(33):1149-56. PubMed ID: 1925442
    [Abstract] [Full Text] [Related]

  • 57. Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin.
    Cassano A, Pozzo C, Corsi DC, Fontana T, Noviello MR, Astone A, Barone C.
    J Cancer Res Clin Oncol; 1995 Aug 17; 121(8):474-7. PubMed ID: 7642690
    [Abstract] [Full Text] [Related]

  • 58. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    de Gramont A, Louvet C, André T, Tournigand C, Krulik M.
    Eur J Cancer; 1998 Apr 17; 34(5):619-26. PubMed ID: 9713264
    [Abstract] [Full Text] [Related]

  • 59. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
    Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A.
    J Clin Oncol; 1995 Jun 17; 13(6):1303-11. PubMed ID: 7751875
    [Abstract] [Full Text] [Related]

  • 60. Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials.
    Raderer M, Scheithauer W.
    Eur J Cancer; 1995 Jun 17; 31A(6):1002-8. PubMed ID: 7646900
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.